Lupin gains on its Nagpur facility receiving EIR from USFDA

12 Nov 2018 Evaluate

Lupin is currently trading at Rs. 869.00, up by 14.80 points or 1.73% from its previous closing of Rs. 854.20 on the BSE.

The scrip opened at Rs. 856.00 and has touched a high and low of Rs. 876.00 and Rs. 854.20 respectively. So far 35407 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 876.00 and Rs. 838.55 respectively. The current market cap of the company is Rs. 39412.25 crore.

The promoters holding in the company stood at 47.00%, while Institutions and Non-Institutions held 37.69% and 15.30% respectively.

Lupin has received the Establishment Inspection report (EIR) post the completion of a Pre-Approval Inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules, carried out by The United States Food and Drug Administration (USFDA) at its Nagpur facility in Maharashtra. The inspection conducted in September 2018 concluded without any observations.

Lupin's Nagpur facility is the company's latest site and manufactures Oral Solid Dosage products. The site also houses company's state of the art injectable manufacturing facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×